Role of Embolization of Thyroid Arteries as a Treatment for Different Thyroid Disorders

Launched by ASSIUT UNIVERSITY · Aug 1, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment called selective embolization of thyroid arteries (SETA) for various thyroid disorders, including Graves disease, goiter, and thyroid cancer. The goal is to see how safe and effective this treatment is for managing these conditions. The trial is currently not recruiting participants, but it aims to involve adults aged 65 to 74 years.

To be eligible for the trial, participants must have specific types of goiter (either diffuse or nodular) or toxic goiter, or they must have thyroid cancer. However, people with certain health issues, like severe bleeding problems or allergies to contrast dye used during the procedure, won't be able to participate. If someone chooses to take part, they can expect to receive close monitoring and care throughout the study. This trial could help improve treatment options for thyroid disorders in the future, so it’s an important step in medical research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• A- diffuse and Nodular goiter:
• B-Toxic goiter:
• C-Thyroid cancer:
• Exclusion Criteria:
• • A. Significant bleeding diathesis. B. Contraindication for contrast media (renal impairment or allergy). C. Severe atherosclerotic disease prevent arterial catheterization. D. Refusal of signing a consent